drugset / Trial / NCT00053391

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

NCT00053391

Phase 1/2 Completed 62 enrolled University Hospital Erlangen
Non-randomizedOpen-labelTreatment

Summary

RATIONALE: Vaccines made from a person's white blood cells mixed with tumor proteins may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have stage III or stage IV melanoma.

Timeline

Start
2002-10
Primary completion
2005-06
Completion
2007-06

Drugs

EvaluationDrugModalityDoseRoute
Subject CD40-ligand Protein / enzyme biologic
Subject autologous dendritic cells Cell therapy Subcutaneous

Indications